// App-Quantinova.ai

192 : Combined Akt and MEK pathway blockade in pre-clinical models of enzalutamide-resistant prostate cancer.

Researchers

Presenter

  • Paul Toren

Principal Investigators

  • Soojin Kim

  • Ladan Fazli

  • Barry Davies

  • Martin Gleave

  • Amina Zoubeidi

Medical Centers

  • Universite Laval, Quebec, QC, Canada

  • Vancouver Prostate Centre, Vancouver, BC, Canada

  • AstraZeneca, Macclesfield, United Kingdom

Locations

  • Canada

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Prostate cancer

Biomarkers

  • N/A

Drug/Treatment

  • Enzalutamide

  • PD0325901

  • PD-0325901

  • Androgen Tear

  • AZD-5363

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved